GoldBamboo.com - Knowledge is strong medicine
  

Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants - Article


  Not Signed In - Sign In / Register


Get Your Free Credit Report Right Now!

Zip Code:






Well Baby Reports

 




Clinical Trial: Investigating the Impact of Tailored Reports on Anxiety Amongst Cancer Patients and Their Confidants

This study has been completed.

Sponsored by: University of Plymouth
Information provided by: University of Plymouth
ClinicalTrials.gov Identifier: NCT00127465

Purpose

Objective: To explore the hypothesis that different methods of selecting and printing information for cancer patients could improve emotional support by affecting interaction with others, and so lead to improved psychological wellbeing.

Design: Randomised trial with 8 groups (three factors, 2X2X2). Data collected at recruitment and three month follow-up.

Participants: 400 patients starting radiotherapy and their ''''confidant'''' (the person in who they confide).

Interventions: Printed booklets. (1) Half had ‘general’ CancerBACUP information for that cancer; half had ‘personal’ information from the medical record plus selected general information; (2) half chose information by ‘interacting’ with the computer; half had a larger volume of material in booklets that were produced ‘automatically’. (3) Half had additional ‘anxiety management advice’.

Outcomes; Patients’ views; use of booklet with others; change in reported social support; change in anxiety and depression.

Condition Intervention Phase
Breast Neoplasms
Prostatic Neoplasms
Laryngeal Neoplasms
Cervix Neoplasms
 Procedure: Issue of information booklet
Phase I
Phase II

MedlinePlus related topics:  Breast Cancer;   Cervical Cancer;   Head and Neck Cancer;   Prostate Cancer
Genetics Home Reference related topics:  breast cancer

Study Type: Interventional
Study Design: Educational/Counseling/Training, Randomized, Open Label, Active Control, Factorial Assignment, Efficacy Study

Official Title: Investigating the Impact of Tailored Reports on Anxiety

Further Study Details: 
Primary Outcomes: patients'''' views three months after intervention;; use of booklet with others between intervention and three month follow up;; change in reported social support between recruitment and three month follow up;; change in anxiety and depression between recruitment and three month follow up.
Secondary Outcomes: confidants'''' views three months after intervention;; change in confidants'''' anxiety and depression between recruitment and three month follow up.
Expected Total Enrollment:  400

Study start: November 2001;  Study completion: July 2005
Last follow-up: July 2003;  Data entry closure: August 2003

Aim:

  • Based on a randomised trial we aimed to model use of leaflets in the home as a function of three factors: (a) whether patients chose the information themselves or if it was chosen for them; (b) whether it included personal information from their own medical record or not; (c) whether it included anxiety management advice or not.
  • We aimed to model patient and confidant''''s anxiety at three months as a function of these three factors and patients’ use of leaflets in the home.

Patient Population: Beatson Oncology Centre. Patients thought to be eligible were to be identified from outpatient appointment diaries over fifteen months. Medical records were to be checked for all those initially identified to ensure that patients have breast, gynaecological, prostate or bladder or testicular, or selected cancers of the head or neck. Patients excluded were to be those: receiving palliative treatment, with no knowledge or understanding of their diagnosis (very few), with visual or mental handicap, with severe pain or symptoms causing distress, medical or nursing students, taking part in other trials with possibly confounding interventions, and those not giving informed consent.

Sample size: We aimed to recruit 400 patients. This was to give 80% power to find a difference between 40% and 27% who have improved anxiety between (eg) 200 in personalised group and 200 in general group.

Recruitment: Eligible patients were to be sent a letter explaining the study and advising them that a researcher will approach them in a visit to the BOC soon after, to seek participation in the study. Patients were not to be recruited at their bad news consultation but as soon as possible thereafter and at any point in their course of contact and treatment at the Beatson. At recruitment the researcher was to further explain the study and seek written consent. If the patient consented the researcher was to arrange a time for the intervention and give the patient a questionnaire to take home to complete themselves and a questionnaire for their ‘confidant’.

Baseline data: Patients were to be asked to bring the completed questionnaire with them to the intervention consultation about one week later. The questionnaire included the following sections: (1) previous computer and information use, perceived knowledge, significant others in providing emotional support, family and living arrangements, (2) a Hospital Anxiety and Depression Scale, (3) a Miller Coping Style questionnaire, (4) Helgeson’s measures of social support and negative interactions. Completion of this questionnaire should have taken about half an hour at home.

Confidants: We aimed to recruit 400 ‘confidants’, one for each patient (but estimated that we were likely to recruit (say) 60% of 400. Patients were to be asked if they were prepared to pass on the baseline questionnaire to a person selected by them as the person they are most likely to use to seek emotional support. This may be a husband, wife, partner, but may also be a daughter, son, or friend. The confidant questionnaire has sections: (1) demographics and relationship to patient, newspaper read, frequency of discussion with patient, perceived knowledge (2)HADS, (3) Miller coping style. We did not know what proportion of patients would be prepared to pass on the questionnaire or what response rate we would get from confidants. Rees in her work with daughters of women with breast cancer found that 93% of patients passed the questionnaires on and 77% of daughters responded. If we got an overall 60% response (ie 240 before and after questionnaires) this would give us 80% power to find a difference between 40% and 23% who had improved anxiety between (eg) 120 in personalised group vs 120 in general group. The confidant population would be less than the patient population. Patients will not be excluded if there is no corresponding ‘confidant’.

Randomisation for the three factors: After recruitment the RA was to randomise for each of the three binary factors (2X2X2 factorial design): A. Interactive v Automatic; B. Medical Record v General; C. Anxiety reducing advice v no advice. Patients were to randomised to the eight sub-groups in blocks of 32 and separately by breast vs rest. The eight (2X2X2) subgroups, each receive different styles of leaflet. These are detailed further below.

Baseline Data: Collected from case notes was to be severity, length of onset of cancer, treatments so far (surgery, radiotherapy, chemotherapy), date of birth, gender, address, deprivation category from postcode for all patients, and a problem and treatment list for patients in the ‘medical record’ groups.

Intervention: The delay between recruitment and intervention was to allow patients time to think about their participation and withdraw if desired. At the intervention, patients were to produce a report about their cancer. Patients in the ‘automatic group’ would not need to use the computer.

  • Interactive vs automatic. Those in the ‘interactive’ groups were to choose from menus, see information on the screen, and press an ‘add to report’ button on information screens for that information which they want to include in their report. Patients’ choices were to be recorded by the computer.
  • Those in the medical records group were to have personal information included based on their medical record. They were to either have information automatically selected and formatted by the computer, or to see it on screen and choose what they want to include.
  • Lastly, half the patients were to have an additional section offering advice for the reduction of anxiety. This section was written based on previous work in cognitive behavioural therapy for anxiety.

All reports were to include colour photos (for example of treatment rooms, staff), and diagrams (for example, anatomical) , good quality printing etc. The patient were to be given the report to take away.

Three month follow-up: At three months patients were to be sent a follow-up questionnaire with the following sections (1) questions about their satisfaction with the information received, their use of their reports, their interactions with their family and friends, and the influence of the reports on these interactions, their perceived knowledge. (2) HADS, (3) Helgeson’s social support questionnaires. Significant others will be sent a questionnaire which has sections on (1) questions about their satisfaction with the information they have received. (2) HADS

Measures of Outcome:

  • Change in anxiety (for patient or confidant) between intervention and 3 month follow-up (HADS)
  • Change in social support (for patient) between intervention and 3 months (Helgeson)
  • Patient satisfaction with information score at 3 month follow-up
  • Confidant satisfaction with information score at 3 month follow-up
  • Whether patient had read report, shown it or discussed it with the named confidant, other family members or friends and whether the discussion was aided by use of the report.
  • What patients liked and disliked about the reports.
  • Amongst the interactive group, choices made between presentation styles and how well these would correspond to automatic computer choices.
  • Patient and staff time, and hence costs, needed for routine delivery of each intervention will be modelled on a variety of assumptions.

Analysis: We were to produce a CONSORT patient flow diagram and compare losses to follow-up by the three interventions (A,B,C). Analysis of outcomes wwas to be (a) for those patients completing both intervention and follow-up. We will focus on the following: (See attached for factors)

  • Comparison of outcomes 1-4 by interventions A, B, and C while controlling for age, gender, cancer site, time since diagnosis, severity, coping style, using analysis of variance (factorial design) and multiple logistic regression.
  • Comparison of outcomes 5 and 6 by interventions A,B, and C (qualitative).
  • Modelling of anxiety (outcomes 1-2) on use of report at home (outcome 4), perceived social support, and interventions A,B,C.
  • Frequencies of choices (outcome 7) and comparison with automatic selection, both statistically and through qualitative description of the differences.
  • Comparison of patient and NHS costs (outcome 8) will be made between the methods used in this trial and other methods of providing information.
  • Comparison of anxiety change in patient and significant other.
  • Analyses will be on those completing follow-up. No substitution of data will be carried out for those randomised but not completing follow-up. We will thus be able to make provisional conclusions on how the different types of information provision influence interaction, anxiety and patient satisfaction, and on the correlation between the use of information with family, and anxiety; We will have information on patient selection to inform the better development of automatic systems, and costs to inform practical deployment.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

Exclusion Criteria:

  • Receiving palliative care
  • Severe pain or symptoms causing distress
  • Having cancer at other sites
  • Having no spoken English
  • Receiving treatment for psychological or psychiatric problems
  • Visual or mental handicap
  • Having case notes not available or ambiguous or illegible.

Location Information


United Kingdom
      Beatson Oncology Centre, Glasgow,  G11 6NT,  United Kingdom

Study chairs or principal investigators

Ray Jones, PhD,  Principal Investigator,  University of Plymouth   

More Information

Study ID Numbers:  ESRC-L328253025
Last Updated:  August 4, 2005
Record first received:  August 4, 2005
ClinicalTrials.gov Identifier:  NCT00127465
Health Authority: United Kingdom: National Health Service
ClinicalTrials.gov processed this record on 2005-08-23

Resources



[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Take control over your directory listings...INSTANTLY

Every day, thousands of users find businesses like yours in the GoldBamboo directory.

Limited Time Offer!!!

For only $30 a year, a savings of 70% off our standard rate:

  • Edit your listing (whenever you want!)
  • Link to your website
  • Choose which categories you are listed in
  • Describe your services

The process will take only a few minutes and consists of 3 easy steps:

1. Register     >     2. Edit Listings     >     3. Publish

Your Company
your street
yourtown, YS 12345
888-888-8888



No Thanks

Popular Treatments

Acne Treatment ADHD Treatment Allergy Treatment Alzheimer's Treatment
Anemia Treatment Arthritis Treatment Asthma Treatment Bipolar Disorder Treatment
Bird Flu Treatment Bladder Cancer Treatment Bladder Control Treatment Blood Pressure Treatment
Brain Tumor Treatment Breast Cancer Treatment Bronchitis Treatment Cancer Treatment
Cancer Alternative Treatment Cataract Treatment Cirrhosis Treatment Colitis Treatment
Colon Cancer Treatment Common Cold Treatment Conjunctivitis Treatment Constipation Treatment
Crohn's Disease Treatment Cystic Fibrosis Treatment Depression Treatment Dermatitis Treatment
Diabetes Treatment Edema Treatment Epilepsy Treatment Erectile Dysfunction Treatment
Fibromyalgia Treatment GERD Treatment Glaucoma Treatment Gout Treatment
Hay Fever Treatment Headache Treatment Heart Disease Treatment Hepatitis Treatment
High Blood Pressure Treatment High Cholesterol Treatment Hives Treatment Hypertension Treatment
Hypoglycemia Treatment IBS Treatment Impotence Treatment Indigestion Treatment
Infertility Treatment Influenza Treatment Insomnia Treatment Lactose Intolerance Treatment
Leukemia Treatment Lung Cancer Treatment Lyme Disease Treatment Macular Degeneration Treatment
Menopause Treatment Migraine Treatment Osteoarthritis Treatment Osteoporosis Treatment
Pancreatic Cancer Treatment PMS Treatment Pneumonia Treatment Prostate Diseases Treatment
Restless Leg Treatment Rheumatoid Arthritis Treatment Sepsis Treatment Sinusitis Treatment
Skin Cancer Treatment Sleep Apnea Treatment Snoring Treatment Stroke Treatment
Testicular Cancer Treatment
GoldBambooTM

Your Integrative Health and Wellness Resource for Well Baby Reports.

December 3, 2009



Page Updated: October 3, 2005
============== Advertisement ==============
Disclaimer: All material displayed on the GoldBamboo.com website is provided for educational purposes only. Consult a physician regarding the applicability of any information found on GoldBamboo.com to your symptoms or medical condition.

Home | About Us | Link To Us | Feedback | Disclaimer | Privacy Policy | Terms of Use | Health Forums

Copyright © 2004-2009 - Anaconda Partners LLC - All rights reserved.

HONcode accreditation seal.

We comply with the HONcode standard for health trust worthy information:
verify here.